Turnstone, which went public via an $80 million IPO in 2023, ended September 2024 with $45.3 million to hand, which the company had been expecting to last into the second quarter of 2026.

The summer of 2023 saw the approval of a new treatment option for certain patients with uveal melanoma, a form of cancer that begins in the eye and remains a challenge to treat. Richard Staines ...

The company is also carrying out a pair of phase 3 trials in cutaneous melanoma – PRISM-MEL-301 and TEBE-AM – and is due to start a third in adjuvant uveal melanoma (ATOM) before year-end.

Do you have blue eyes? We talked to experts to discover curious facts about baby blues, including whether your biological family is bigger than you ever imagined.

Shares of Immunocore Holdings plc (NASDAQ:IMCR – Get Free Report) have received an average recommendation of “Moderate Buy” from the thirteen research firms that are currently covering the firm, ...

The healthcare industry is set for growth due to advancements in targeted treatments and personalized care and the rapid ...

2021)], which is beginning to expand into other solid tumour types with a phase I trial examining the safety and tolerability of IOA-244 in uveal melanoma patients currently recruiting participants ...

SAN DIEGO - Turnstone Biologics Corp. (NASDAQ:TSBX), a clinical-stage biotechnology company with a market capitalization of $9.45 million, has announced the discontinuation of its TIDAL-01 clinical ...

The lab of The Wistar Institute's Jessie Villanueva, Ph.D., has identified a new strategy for attacking treatment-resistant ...

The lab of The Wistar Institute's Jessie Villanueva, Ph.D., has identified a new strategy for attacking treatment-resistant melanoma: inhibiting the gene S6K2. .

Melanoma is a fast-progressing skin cancer characterized by a high mortality rate after metastasis. Local chemotherapy could ...